Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Monday, 12 / 10 / 2018

Welcome to JCTH

scover V6I1  
 
 

Table of Contents

Original Article

Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review
Duminda Suraweera, Christina Fanous, Melissa Jimenez, Myron J. Tong, Sammy Saab
[ Abstract ] [ Html ] [ PDF Full-text ] 119-126 Doi: 10.14218/JCTH.2017.00064

Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury
Meir Mizrahi, Tomer Adar, Gadi Lalazar, Dean Nachman, Madi El Haj, Ami Ben Ya’acov, Yoav Lichtenstein, Yehudit Shabat, Dimitri Kanovich, Lida Zolotarov, Yaron Ilan
[ Abstract ] [ Html ] [ PDF Full-text ] 127-134 Doi: 10.14218/JCTH.2017.00071

Vitamin D Deficiency and Its Relationship with Child-Pugh Class in Patients with Chronic Liver Disease
Zubia Jamil, Sharmin Arif, Anum Khan, Asghar Aurangzeb Durrani, Nayyar Yaqoob
[ Abstract ] [ Html ] [ PDF Full-text ] 135-140 Doi: 10.14218/JCTH.2017.00055

Effect of Genistein in Comparison with Trichostatin A on Reactivation of DNMTs Genes in Hepatocellular Carcinoma
Masumeh Sanaei, Fraidoon Kavoosi, Abazar Roustazadeh, Fatemeh Golestan
[ Abstract ] [ Html ] [ PDF Full-text ] 141-146 Doi: 10.14218/JCTH.2018.00002

HCV Therapy Follow-up Fractionation (CTF2) by Intra-PBMC Nested RNA PCR Recognizes Early Virologic Response and Relapse
Mohamed Darwish Ahmed Abd Alla, Saleh Ahmed Elibiary, Ramy Hassan Elshaboury, George Y. Wu, Reham M. Dawood, Mostafa Kamel El Awady
[ Abstract ] [ Html ] [ PDF Full-text ] 147-154 Doi: 10.14218/JCTH.2017.00077

Review Article

Occult Hepatitis C Virus Infection: A Review
Alyssa Austria, George Y. Wu
[ Abstract ] [ Html ] [ PDF Full-text ] 155-160 Doi: 10.14218/JCTH.2017.00053

Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies
Wolfgang Poller, Arash Haghikia, Mario Kasner, Ziya Kaya, Udo Bavendiek, Heiner Wedemeier, Hans-J?rg Epple, Carsten Skurk, Ulf Landmesser
[ Abstract ] [ Html ] [ PDF Full-text ] 161-167 Doi: 10.14218/JCTH.2017.00057

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Heather S. Snyder, Sami A. Sakaan, Katherine L. March, Osama Siddique, Rosann Cholankeril, Carolyn D. Cummings, Chiran Gadiparthi, Sanjaya K. Satapathy, Aijaz Ahmed, George Cholankeril
[ Abstract ] [ Html ] [ PDF Full-text ] 168-174 Doi: 10.14218/JCTH.2017.00050

Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
Patrick Vande Lune, Ahmed K. Abdel Aal, Sergio Klimkowski, Jessica G. Zarzour, Andrew J. Gunn
[ Abstract ] [ Html ] [ PDF Full-text ] 175-188 Doi: 10.14218/JCTH.2017.00045

Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review
Shamar Young, Andrew J. Taylor, Tina Sanghvi
[ Abstract ] [ Html ] [ PDF Full-text ] 189-197 Doi: 10.14218/JCTH.2017.00059

Non-invasive in vivo Imaging Grading of Liver Fibrosis
Hanyu Jiang, Tianying Zheng, Ting Duan, Jie Chen, Bin Song
[ Abstract ] [ Html ] [ PDF Full-text ] 198-207 Doi: 10.14218/JCTH.2017.00038

Differentiating Cystic Liver Lesions: A Review of Imaging Modalities, Diagnosis and Management
Marianna G. Mavilia, Tina Pakala, Marco Molina, George Y. Wu
[ Abstract ] [ Html ] [ PDF Full-text ] 208-216 Doi: 10.14218/JCTH.2017.00069

Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease
Shujing Lv, Sushan Jiang, Shousheng Liu, Quanjiang Dong, Yongning Xin, Shiying Xuan
[ Abstract ] [ Html ] [ PDF Full-text ] 217-221 Doi: 10.14218/JCTH.2018.00021

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners
Francesca Patella, Filippo Pesapane, Enrico Maria Fumarola, Ilaria Emili, Riccardo Spairani, Salvatore Alessio Angileri, Silvia Tresoldi, Giuseppe Franceschelli, Gianpaolo Carrafiello
[ Abstract ] [ Html ] [ PDF Full-text ] 222-236 Doi: 10.14218/JCTH.2017.00062

Case Report

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series
Dominik Bettinger, Stefan Schlabe, Sven Pischke, Michael R. Mallmann, Mignon-Denise Keyver-Paik, Walther Kuhn, Christian P. Strassburg, Robert Thimme, Ulrich Spengler
[ Abstract ] [ Html ] [ PDF Full-text ] 237-240 Doi: 10.14218/JCTH.2017.00063

ORIGINAL ARTICLE

Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review

Duminda Suraweera1, Christina Fanous2, Melissa Jimenez2, Myron J. Tong3 and Sammy Saab*2,4

1Department of Medicine, Olive-View Medical Center, Sylmar, CA, USA
2Department of Surgery at the University of California at Los Angeles, Los Angeles, CA, USA
3Huntington Research Institute, Pasadena, CA, USA
4Department of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA

*Correspondence to: Sammy Saab, Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095, USA. Tel: +1-310-206-6705, Fax: +1-310-206-4197, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(2):119-126 DOI: 10.14218/JCTH.2017.00064
Received: October 7, 2017 Accepted: January 2, 2018 Published online: February 14, 2018

Abstract

Background and Aims: Hypercholesterolemia is a common finding in patients with primary biliary cholangitis (PBC) and is a well-defined risk factor for cardiovascular disease. However, studies have been mixed on whether PBC patients do, in fact, have higher cardiovascular risk. The aim of this study is to review the current literature and provide an evidence-based assessment of cardiovascular risk in PBC patients.

Methods: We performed a systematic literature search on PubMed regarding patients with PBC and cardiovascular events from the database inception to July 1, 2017. A total of 33 articles fulfilling our inclusion criteria were found.

Results: The majority of the studies evaluated yielded no statistically significant difference in cardiovascular disease in the PBC population compared to the general public. However, some reports found a statistically significantly increase in coronary artery disease. Several studies have looked at the specific lipid profile of patients with PBC with hypocholesteremia. While these lipid abnormalities differ by stage of disease, there is evidence to suggest that the specific lipid profile in PBC may have lower atherogenicity than in patients with hypercholesterolemia without PBC. Studies looking at patients with PBC with other risk factors for cardiovascular disease, such as hypertension and metabolic syndrome, have consistently found a higher risk for cardiovascular disease in these patients. Statin treatment is effective in reducing lipid levels and possibly improving endothelial inflammation in patients with PBC with hypercholesterolemia.

Conclusions: There is not enough evidence to suggest an increased risk of cardiovascular disease in patients with PBC with hypercholesterolemia, except for those individuals with concomitant features of metabolic syndrome. In patients with PBC with no additional cardiovascular risk factors, individual risk/benefit discussion on lipid-lowering treatment should be considered.

Keywords

Primary biliary cholangitis (PBC), Cardiovascular risk, Hypercholesterolemia

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 119-126  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 

ORIGINAL ARTICLE

Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury

Meir Mizrahi, Tomer Adar, Gadi Lalazar, Dean Nachman, Madi El Haj, Ami Ben Ya’acov, Yoav Lichtenstein, Yehudit Shabat, Dimitri Kanovich, Lida Zolotarov and Yaron Ilan*

Gastroenterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

*Correspondence to: Yaron Ilan, Department of Medicine, Hebrew University-Hadassah Medical Center, P.O.B 12000, Jerusalem, IL-91120, Israel. Tel: +972-2-6777816, Fax: +972-2-6431021, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(2):127-134 DOI: 10.14218/JCTH.2017.00071
Received: November 4, 2017 Accepted: January 23, 2018 Published online: February 14, 2018

Abstract

Background and Aims: Acetaminophen (APAP) and HMG-CoA reductase inhibitors are common causes of drug-induced liver injury (DILI). This study aimed to determine the ability to reduce APAP- and statins-mediated liver injury by using formulations that combine glycosphingolipids and vitamin E.

Methods: Mice were injected with APAP or with statins and treated before and after with β-glucosylceramide (GC), with or without vitamin E. Mice were followed for changes in liver enzymes, liver histology, hepatic expression of JNK, STAT3 and caspase 3, as well as intrahepatic natural killer T cells (NKT) and the serum cytokine levels by flow cytometry.

Results: Administration of GC before or after APAP alleviated the liver damage, as noted by a reduction of the liver enzymes, improvement in the liver histology and decreased hepatic caspase 3 expression. Beneficial effect was associated with a reduction of the intrahepatic NKT, JNK expression in the liver, and increased glutathione in the liver, and decreased TNF-α serum levels. Synergistic effect of co-administration of GC with vitamin E was observed. Similar protective effect of GC on statin-mediated liver damage was documented by a reduction in liver enzymes and improved liver histology, which was mediated by reduction of NKT, increased STAT3 expression in the liver, and reduced the TGF-β and IL17 levels.

Conclusions: β-glycosphingolipids exert a hepatoprotective effect on APAP- and statins-mediated liver damage. Vitamin E exerted a synergistic effect to that of GC. The generation of “safer drug” formulations, which include an active molecule combined with a hepatoprotective adjuvant, may provide an answer to the real unmet need of DILI.

Keywords

Acetaminophen, Statins, Glycosphingolipids

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 127-134  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home Vol 6 Issue 2